Nektar Therapeutics announced that NKTR-102 has been given orphan drug status by the FDA for the treatment of women with ovarian cancer. NKTR-102 is in an ongoing, Phase 2 study, enrolling approximately 125 patients with platinum-resistant ovarian cancer whose disease has progressed following treatment with pegylated liposomal doxorubicin (PLD) therapy.
NKTR-102 is a next-generation topoisomerase I inhibitor with reduced peak concentrations and continuous concentration profile. It is currently an investigational agent and is not approved by the FDA, European Medicines Agency (EMA) or other Health Authorities.
For more information call (415) 482-5300 or visit www.nektar.com.